Incus Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Incus Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, grow…

2009-10-21 Ernakulam, Kerala Active Unlisted Active Compliant
Share
Connect MCP
IP Incus Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Incus Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
88/100
Trust Score
Low Risk

Incus Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 88/100. Incus Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2009, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 10 Aug 2026 from the latest processed filings. Incus Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 5 open (67.29 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India1 48.0 cr
Bank Of India2 48.0 cr
Others1 48.0 cr
Hdfc Bank Limited1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
THULASEEDHARAN PILLAI SURESH KUMAR 01234567 Director 01/04/2018 6 yrs Approved
NARAYANAN PRIYARANJAN DAS 01234567 Director 01/04/2018 6 yrs Approved
BABU PHILIP 01234567 Director 01/04/2018 6 yrs Approved
PLAMMOOTTIL JANARDHANAN PILLAI ABHILASH 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • PLAMMOOTTIL JANARDHANAN PILLAI ABHILASH has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: THULASEEDHARAN PILLAI SURESH KUMAR (Whole-time director) · NARAYANAN PRIYARANJAN DAS (Managing Director) · BABU PHILIP (Whole-time director) · PLAMMOOTTIL JANARDHANAN PILLAI ABHILASH (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
Operating for 16+ years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 1.42 in a year.
5 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence90/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment76/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 5 open charge(s) of 67.29 Lakh already registered.
  • Compliance record supports lending.
Investor view93/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
08 Apr 2025
Charge created
Others - 13.80 Lakh
31 Mar 2025
Latest balance sheet
Filed with ROC
03 Mar 2025
Charge created
Bank Of India - 7.91 Lakh
08 May 2024
Charge created
Bank Of India - 10.27 Lakh
08 Dec 2022
Director appointed
PLAMMOOTTIL JANARDHANAN PILLAI ABHILASH (Whole-time director)
27 Jun 2022
Charge created
Hdfc Bank Limited - 7.31 Lakh
17 Oct 2019
Charge created
State Bank Of India - 28.00 Lakh
29 Feb 2016
Director ceased
THULASEEDHARAN PILLAI SURESH KUMAR
Director ceased
BABU PHILIP
Director ceased
PLAMMOOTTIL JANARDHANAN PILLAI ABHILASH
01 Feb 2013
Securities allotted
39000.00 Equity Shares - 3.90 Lakh raised
21 Oct 2009
Incorporated
Registered with Roc Ernakulam
Director appointed
THULASEEDHARAN PILLAI SURESH KUMAR (Whole-time director)
Director appointed
NARAYANAN PRIYARANJAN DAS (Managing Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
S.D.S.Shipping Pvt Ltd U99999MH1985PTC036129 Mumbai, Maharashtra, India
Teva Pharmaceuticals U73100MH2000PTC405989 Mumbai, Maharashtra, India
Corstone Development India Private Limited U74999DL2021PTC390330 Delhi, Delhi, India
Lorryzone Technologies Ad On Logistics Vehicle U72200UP2015PTC092164 Noida, Uttar Pradesh, India
Kraftwood Decor Private Limited U93000WB2013PTC193552 Kolkata, West Bengal, India
Viscom Machine Vision (India) Private Limited U29306KA2021FTC154922 Bangalore, Karnataka, India
Eduonix Learning Solution U72300MH2013PTC250755 Navi Mumbai, Maharashtra, India
Verif Works U72900KA2016PTC095757 Bangalore, Karnataka, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Incus Pharmaceuticals Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Incus Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Incus Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Incus Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Incus Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Incus Pharmaceuticals Private Limited an active company?

Incus Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Incus Pharmaceuticals Private Limited financially healthy?

Incus Pharmaceuticals Private Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Incus Pharmaceuticals Private Limited?

Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Incus Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Incus Pharmaceuticals Private Limited have loans or charges against its assets?

5 open charge(s) are registered against its assets.

Is Incus Pharmaceuticals Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Incus Pharmaceuticals Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.